This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Piretanide
Accession Number
DB02925  (EXPT03308)
Type
Small Molecule
Groups
Approved
Description

Piretanide (INN, trade names Arelix, Eurelix, Tauliz) has been synthesized in 1973 at Hoechst AG (Germany) as a loop diuretic compound by using a then-new method for introducing cyclic amine residues in an aromatic nucleus in the presence of other aromatically bonded functional groups.

Structure
Thumb
Synonyms
Not Available
External IDs
HOE 118 / HOE-118 / S 73 4118 / S-73-4118
International/Other Brands
Arelix / Eurelix / Tauliz
Categories
UNII
DQ6KK6GV93
CAS number
55837-27-9
Weight
Average: 362.4
Monoisotopic: 362.093642386
Chemical Formula
C17H18N2O5S
InChI Key
UJEWTUDSLQGTOA-UHFFFAOYSA-N
InChI
InChI=1S/C17H18N2O5S/c18-25(22,23)15-11-12(17(20)21)10-14(19-8-4-5-9-19)16(15)24-13-6-2-1-3-7-13/h1-3,6-7,10-11H,4-5,8-9H2,(H,20,21)(H2,18,22,23)
IUPAC Name
4-phenoxy-3-(pyrrolidin-1-yl)-5-sulfamoylbenzoic acid
SMILES
NS(=O)(=O)C1=CC(=CC(N2CCCC2)=C1OC1=CC=CC=C1)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
USolute carrier family 12 member 1
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe therapeutic efficacy of Piretanide can be decreased when used in combination with (4R)-limonene.Investigational
16-Bromoepiandrosterone16-Bromoepiandrosterone may increase the hypokalemic activities of Piretanide.Investigational
19-norandrostenedione19-norandrostenedione may increase the hypokalemic activities of Piretanide.Experimental, Illicit
5-androstenedione5-androstenedione may increase the hypokalemic activities of Piretanide.Experimental, Illicit
AbediterolAbediterol may increase the hypokalemic activities of Piretanide.Investigational
AcarboseThe therapeutic efficacy of Acarbose can be increased when used in combination with Piretanide.Approved, Investigational
AceclofenacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcetyldigitoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Acetyldigitoxin.Approved
AcetyldigoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Acetyldigoxin.Experimental
Acetylsalicylic acidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Adapalene.Approved
AlclofenacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlclometasoneAlclometasone may increase the hypokalemic activities of Piretanide.Approved
AlcuroniumPiretanide may decrease the neuromuscular blocking activities of Alcuronium.Experimental
AldosteroneAldosterone may increase the hypokalemic activities of Piretanide.Experimental, Investigational
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Piretanide.Approved, Illicit
AllopurinolThe risk or severity of adverse effects can be increased when Piretanide is combined with Allopurinol.Approved
AlminoprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Alminoprofen.Experimental
AloxiprinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Aloxiprin.Experimental
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Piretanide.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Piretanide.Illicit
AmcinonideAmcinonide may increase the hypokalemic activities of Piretanide.Approved
AmikacinThe serum concentration of Amikacin can be increased when it is combined with Piretanide.Approved, Investigational, Vet Approved
Aminosalicylic AcidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Aminosalicylic Acid.Approved
AndrographolideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Andrographolide.Investigational
AndrostenedioneAndrostenedione may increase the hypokalemic activities of Piretanide.Experimental, Illicit
AnecortaveAnecortave may increase the hypokalemic activities of Piretanide.Investigational
anecortave acetateanecortave acetate may increase the hypokalemic activities of Piretanide.Investigational
AnisodamineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Anisodamine.Investigational
AntipyrineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Antipyrine.Approved, Investigational
ApocyninThe therapeutic efficacy of Piretanide can be decreased when used in combination with Apocynin.Investigational
ApramycinThe serum concentration of Apramycin can be increased when it is combined with Piretanide.Experimental, Vet Approved
ApremilastThe therapeutic efficacy of Piretanide can be decreased when used in combination with Apremilast.Approved, Investigational
ArbekacinThe serum concentration of Arbekacin can be increased when it is combined with Piretanide.Approved, Investigational
ArbutamineArbutamine may increase the hypokalemic activities of Piretanide.Approved
ArformoterolArformoterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
AtamestaneAtamestane may increase the hypokalemic activities of Piretanide.Investigational
AtracuriumPiretanide may decrease the neuromuscular blocking activities of Atracurium.Approved, Experimental, Investigational
Atracurium besylatePiretanide may decrease the neuromuscular blocking activities of Atracurium besylate.Approved
AzapropazoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Balsalazide.Approved, Investigational
BambuterolBambuterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of hypokalemia can be increased when Beclomethasone dipropionate is combined with Piretanide.Approved, Investigational
BekanamycinThe serum concentration of Bekanamycin can be increased when it is combined with Piretanide.Experimental
BenazeprilPiretanide may increase the hypotensive activities of Benazepril.Approved, Investigational
BendazacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Bendazac.Experimental
BenorilateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Benzydamine.Approved
BetamethasoneBetamethasone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
BevoniumThe therapeutic efficacy of Piretanide can be decreased when used in combination with Bevonium.Experimental
BezitramideThe risk or severity of adverse effects can be increased when Bezitramide is combined with Piretanide.Experimental, Illicit, Withdrawn
BisacodylThe risk or severity of adverse effects can be increased when Piretanide is combined with Bisacodyl.Approved
BitolterolBitolterol may increase the hypokalemic activities of Piretanide.Withdrawn
BromfenacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Bromfenac.Approved
BucillamineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Bucillamine.Investigational
BudesonideThe risk or severity of hypokalemia can be increased when Budesonide is combined with Piretanide.Approved
BufexamacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Bufexamac.Approved, Experimental
BumadizoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Bumadizone.Experimental
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Piretanide.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Piretanide.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of hypotension can be increased when Canagliflozin is combined with Piretanide.Approved
Candesartan cilexetilThe risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Piretanide.Approved
CandoxatrilPiretanide may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilPiretanide may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe therapeutic efficacy of Piretanide can be decreased when used in combination with Carbaspirin calcium.Experimental, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Piretanide.Illicit, Investigational, Vet Approved
CarprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Piretanide can be decreased when used in combination with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypokalemic activities of Piretanide.Approved, Investigational
ChloroquineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Chloroquine.Approved, Investigational, Vet Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CiclesonideCiclesonide may increase the hypokalemic activities of Piretanide.Approved, Investigational
CilazaprilPiretanide may increase the hypotensive activities of Cilazapril.Approved
CisatracuriumPiretanide may decrease the neuromuscular blocking activities of Cisatracurium.Approved
CisplatinThe risk or severity of ototoxicity and nephrotoxicity can be increased when Piretanide is combined with Cisplatin.Approved
ClenbuterolClenbuterol may increase the hypokalemic activities of Piretanide.Approved, Investigational, Vet Approved
ClobetasolClobetasol may increase the hypokalemic activities of Piretanide.Approved, Investigational
Clobetasol propionateClobetasol propionate may increase the hypokalemic activities of Piretanide.Approved
ClobetasoneClobetasone may increase the hypokalemic activities of Piretanide.Approved
ClocortoloneClocortolone may increase the hypokalemic activities of Piretanide.Approved
ClonixinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Clonixin.Approved
CodeineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Codeine.Approved, Illicit
ColesevelamColesevelam can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Piretanide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateCortexolone 17α-propionate may increase the hypokalemic activities of Piretanide.Investigational
CorticosteroneCorticosterone may increase the hypokalemic activities of Piretanide.Experimental
Cortisone acetateCortisone acetate may increase the hypokalemic activities of Piretanide.Approved, Investigational
CurcuminThe therapeutic efficacy of Piretanide can be decreased when used in combination with Curcumin.Approved, Investigational
CyclosporineThe risk or severity of adverse effects can be increased when Cyclosporine is combined with Piretanide.Approved, Investigational, Vet Approved
CymarinThe risk or severity of adverse effects can be increased when Piretanide is combined with Cymarin.Experimental
DapagliflozinThe therapeutic efficacy of Dapagliflozin can be increased when used in combination with Piretanide.Approved
DecamethoniumPiretanide may decrease the neuromuscular blocking activities of Decamethonium.Approved
DeflazacortDeflazacort may increase the hypokalemic activities of Piretanide.Approved, Investigational
DelaprilPiretanide may increase the hypotensive activities of Delapril.Investigational
DersalazineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Dersalazine.Investigational
DeslanosideThe risk or severity of adverse effects can be increased when Piretanide is combined with Deslanoside.Approved
DesonideDesonide may increase the hypokalemic activities of Piretanide.Approved, Investigational
DesoximetasoneDesoximetasone may increase the hypokalemic activities of Piretanide.Approved
Desoxycorticosterone acetateDesoxycorticosterone acetate may increase the hypokalemic activities of Piretanide.Approved
Desoxycorticosterone PivalateDesoxycorticosterone Pivalate may increase the hypokalemic activities of Piretanide.Experimental, Vet Approved
DexamethasoneThe risk or severity of hypokalemia can be increased when Dexamethasone is combined with Piretanide.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateDexamethasone isonicotinate may increase the hypokalemic activities of Piretanide.Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Piretanide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Piretanide.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Piretanide.Approved, Investigational
DibekacinThe serum concentration of Dibekacin can be increased when it is combined with Piretanide.Experimental
DiclofenacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DifenpiramideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Difenpiramide.Experimental
DiflorasoneDiflorasone may increase the hypokalemic activities of Piretanide.Approved
DiflunisalThe therapeutic efficacy of Piretanide can be decreased when used in combination with Diflunisal.Approved, Investigational
DifluocortoloneDifluocortolone may increase the hypokalemic activities of Piretanide.Approved, Investigational, Withdrawn
DifluprednateDifluprednate may increase the hypokalemic activities of Piretanide.Approved
DigitoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Digitoxin.Approved, Investigational
DigoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin.Approved
Digoxin Immune Fab (Ovine)The risk or severity of adverse effects can be increased when Piretanide is combined with Digoxin Immune Fab (Ovine).Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Piretanide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Piretanide.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Piretanide.Experimental, Illicit
DihydrostreptomycinThe serum concentration of Dihydrostreptomycin can be increased when it is combined with Piretanide.Investigational, Vet Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Piretanide.Approved, Illicit
DipivefrinDipivefrin may increase the hypokalemic activities of Piretanide.Approved
DobutamineDobutamine may increase the hypokalemic activities of Piretanide.Approved
DocusateThe risk or severity of adverse effects can be increased when Piretanide is combined with Docusate.Approved
DofetilideThe risk or severity of QTc prolongation, torsade de pointes, hypokalemia, hypomagnesemia, and cardiac arrest can be increased when Piretanide is combined with Dofetilide.Approved, Investigational
Domoic AcidPiretanide may decrease the neuromuscular blocking activities of Domoic Acid.Experimental
DoxacuriumPiretanide may decrease the neuromuscular blocking activities of Doxacurium chloride.Approved
DoxofyllineDoxofylline may increase the hypokalemic activities of Piretanide.Approved, Investigational
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Piretanide.Experimental
DroxicamThe therapeutic efficacy of Piretanide can be decreased when used in combination with Droxicam.Withdrawn
DroxidopaDroxidopa may increase the hypokalemic activities of Piretanide.Approved, Investigational
DuvelisibThe therapeutic efficacy of Piretanide can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Piretanide can be decreased when used in combination with E-6201.Investigational
EnalaprilPiretanide may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPiretanide may increase the hypotensive activities of Enalaprilat.Approved
EphedraEphedra may increase the hypokalemic activities of Piretanide.Approved, Nutraceutical, Withdrawn
EpinephrineEpinephrine may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
EpirizoleThe therapeutic efficacy of Piretanide can be decreased when used in combination with Epirizole.Approved
EquileninEquilenin may increase the hypokalemic activities of Piretanide.Experimental
EquilinEquilin may increase the hypokalemic activities of Piretanide.Approved
EstroneEstrone may increase the hypokalemic activities of Piretanide.Approved
Estrone sulfateEstrone sulfate may increase the hypokalemic activities of Piretanide.Approved
EtafedrineEtafedrine may increase the hypokalemic activities of Piretanide.Approved
EtanerceptThe therapeutic efficacy of Piretanide can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Ethenzamide.Experimental
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Piretanide.Approved, Illicit
EtodolacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Piretanide can be decreased when used in combination with Etoricoxib.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Piretanide.Illicit, Vet Approved
Evening primrose oilThe therapeutic efficacy of Piretanide can be decreased when used in combination with Evening primrose oil.Investigational, Nutraceutical
ExisulindThe therapeutic efficacy of Piretanide can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Felbinac.Experimental
FenbufenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Fenoprofen.Approved
FenoterolFenoterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
FentanylThe therapeutic efficacy of Piretanide can be decreased when used in combination with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FentiazacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Ferulic acid.Experimental
FloctafenineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluasteroneFluasterone may increase the hypokalemic activities of Piretanide.Investigational
FludrocortisoneFludrocortisone may increase the hypokalemic activities of Piretanide.Approved, Investigational
FlumethasoneFlumethasone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
FlunisolideFlunisolide may increase the hypokalemic activities of Piretanide.Approved, Investigational
FlunixinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Flunoxaprofen.Experimental
Fluocinolone AcetonideFluocinolone Acetonide may increase the hypokalemic activities of Piretanide.Approved, Investigational, Vet Approved
FluocinonideFluocinonide may increase the hypokalemic activities of Piretanide.Approved, Investigational
FluocortoloneFluocortolone may increase the hypokalemic activities of Piretanide.Approved, Withdrawn
FluorometholoneFluorometholone may increase the hypokalemic activities of Piretanide.Approved, Investigational
FluprednideneFluprednidene may increase the hypokalemic activities of Piretanide.Approved, Withdrawn
FluprednisoloneFluprednisolone may increase the hypokalemic activities of Piretanide.Approved
FlurandrenolideFlurandrenolide may increase the hypokalemic activities of Piretanide.Approved
FlurbiprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FluticasoneFluticasone may increase the hypokalemic activities of Piretanide.Approved, Experimental, Investigational
Fluticasone furoateFluticasone furoate may increase the hypokalemic activities of Piretanide.Approved
Fluticasone propionateThe risk or severity of hypokalemia can be increased when Fluticasone propionate is combined with Piretanide.Approved
FormestaneFormestane may increase the hypokalemic activities of Piretanide.Approved, Investigational, Withdrawn
FormoterolFormoterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
FoscarnetPiretanide may decrease the excretion rate of Foscarnet which could result in a higher serum level.Approved
FosinoprilPiretanide may increase the hypotensive activities of Fosinopril.Approved
FosphenytoinFosphenytoin may decrease the diuretic activities of Piretanide.Approved, Investigational
FramycetinThe serum concentration of Framycetin can be increased when it is combined with Piretanide.Approved
GallaminePiretanide may decrease the neuromuscular blocking activities of Gallamine.Experimental
Gallamine TriethiodidePiretanide may decrease the neuromuscular blocking activities of Gallamine Triethiodide.Approved
GeneticinThe serum concentration of Geneticin can be increased when it is combined with Piretanide.Experimental
GentamicinThe serum concentration of Gentamicin can be increased when it is combined with Piretanide.Approved, Vet Approved
GENTAMICIN C1AThe serum concentration of GENTAMICIN C1A can be increased when it is combined with Piretanide.Experimental
GitoformateThe risk or severity of adverse effects can be increased when Piretanide is combined with Gitoformate.Experimental
GlimepirideThe therapeutic efficacy of Glimepiride can be increased when used in combination with Piretanide.Approved
GlipizideThe therapeutic efficacy of Glipizide can be increased when used in combination with Piretanide.Approved, Investigational
GlyburideThe therapeutic efficacy of Glyburide can be increased when used in combination with Piretanide.Approved
GlycerinThe risk or severity of adverse effects can be increased when Piretanide is combined with Glycerin.Approved, Investigational
GuacetisalThe therapeutic efficacy of Piretanide can be decreased when used in combination with Guacetisal.Experimental
HalcinonideHalcinonide may increase the hypokalemic activities of Piretanide.Approved, Investigational, Withdrawn
HE3286HE3286 may increase the hypokalemic activities of Piretanide.Investigational
Hemoglobin crosfumarilThe therapeutic efficacy of Piretanide can be decreased when used in combination with Hemoglobin crosfumaril.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Piretanide.Approved, Illicit, Investigational
HexoprenalineHexoprenaline may increase the hypokalemic activities of Piretanide.Approved, Withdrawn
HigenamineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Higenamine.Investigational
HydrocodoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Hydrocodone.Approved, Illicit
HydrocortisoneThe risk or severity of hypokalemia can be increased when Hydrocortisone is combined with Piretanide.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of hypokalemia can be increased when Hydrocortisone acetate is combined with Piretanide.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of hypokalemia can be increased when Hydrocortisone butyrate is combined with Piretanide.Approved, Vet Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Piretanide.Approved, Illicit
Hygromycin BThe serum concentration of Hygromycin B can be increased when it is combined with Piretanide.Vet Approved
IbandronateThe risk or severity of hypocalcemia can be increased when Piretanide is combined with Ibandronate.Approved, Investigational
IbuprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Piretanide can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Piretanide can be decreased when used in combination with Icatibant.Approved, Investigational
ImidaprilPiretanide may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Imidazole salicylate.Experimental
IndacaterolIndacaterol may increase the hypokalemic activities of Piretanide.Approved
IndobufenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Indoprofen.Withdrawn
IsepamicinThe serum concentration of Isepamicin can be increased when it is combined with Piretanide.Experimental
IsoetarineIsoetarine may increase the hypokalemic activities of Piretanide.Approved
IsoprenalineIsoprenaline may increase the hypokalemic activities of Piretanide.Approved, Investigational
IsoxicamThe therapeutic efficacy of Piretanide can be decreased when used in combination with Isoxicam.Withdrawn
IstaroximeIstaroxime may increase the hypokalemic activities of Piretanide.Investigational
IvabradinePiretanide may increase the arrhythmogenic activities of Ivabradine.Approved
KanamycinThe serum concentration of Kanamycin can be increased when it is combined with Piretanide.Approved, Investigational, Vet Approved
KebuzoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Kebuzone.Experimental
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Piretanide.Approved, Investigational
KetoprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Ketorolac.Approved
LactuloseThe risk or severity of adverse effects can be increased when Piretanide is combined with Lactulose.Approved
Lanatoside CThe risk or severity of adverse effects can be increased when Piretanide is combined with Lanatoside C.Experimental
LeflunomideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Leflunomide.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Piretanide.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Piretanide.Approved
LevosalbutamolLevosalbutamol may increase the hypokalemic activities of Piretanide.Approved, Investigational
LicoriceThe risk or severity of hypokalemia can be increased when Licorice is combined with Piretanide.Approved
LisinoprilPiretanide may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisofyllineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be decreased when it is combined with Piretanide.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Piretanide.Illicit
LonazolacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Piretanide can be decreased when used in combination with Lornoxicam.Approved, Investigational
LoteprednolLoteprednol may increase the hypokalemic activities of Piretanide.Approved
LoxoprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Piretanide can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium carbonateThe risk or severity of adverse effects can be increased when Piretanide is combined with Magnesium carbonate.Approved, Investigational
Magnesium citrateThe risk or severity of adverse effects can be increased when Piretanide is combined with Magnesium citrate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Piretanide is combined with Magnesium hydroxide.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Magnesium salicylate.Approved
Magnesium sulfateThe risk or severity of adverse effects can be increased when Piretanide is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MasoprocolThe therapeutic efficacy of Piretanide can be decreased when used in combination with Masoprocol.Approved, Investigational
ME-609ME-609 may increase the hypokalemic activities of Piretanide.Investigational
Meclofenamic acidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
MedrysoneMedrysone may increase the hypokalemic activities of Piretanide.Approved
Mefenamic acidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Mefenamic acid.Approved
MelengestrolMelengestrol may increase the hypokalemic activities of Piretanide.Vet Approved
MeloxicamThe therapeutic efficacy of Piretanide can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Piretanide.Experimental
MesalazineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Piretanide can be decreased when used in combination with Metamizole.Approved, Investigational, Withdrawn
MetforminThe therapeutic efficacy of Metformin can be increased when used in combination with Piretanide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Piretanide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Piretanide.Approved, Illicit
MethotrexateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Methotrexate.Approved
Methyl salicylateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Methyl salicylate.Approved, Vet Approved
MethylprednisoloneThe risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Piretanide.Approved, Vet Approved
MetildigoxinThe risk or severity of adverse effects can be increased when Piretanide is combined with Metildigoxin.Experimental
MetocurinePiretanide may decrease the neuromuscular blocking activities of Metocurine.Approved
Metocurine IodidePiretanide may decrease the neuromuscular blocking activities of Metocurine Iodide.Approved, Withdrawn
MicronomicinThe serum concentration of Micronomicin can be increased when it is combined with Piretanide.Experimental
Mineral oilThe risk or severity of adverse effects can be increased when Piretanide is combined with Mineral oil.Approved, Vet Approved
MivacuriumPiretanide may decrease the neuromuscular blocking activities of Mivacurium.Approved
MizoribineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Mizoribine.Investigational
MoexiprilPiretanide may increase the hypotensive activities of Moexipril.Approved
MofebutazoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Mofebutazone.Experimental
MometasoneMometasone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Piretanide.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Piretanide can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Mycophenolic acid.Approved
NabumetoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Nabumetone.Approved
NafamostatThe therapeutic efficacy of Piretanide can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Naftifine.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Piretanide.Approved
NaproxenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Naproxen.Approved, Vet Approved
NCX 1022NCX 1022 may increase the hypokalemic activities of Piretanide.Investigational
NeamineThe serum concentration of Neamine can be increased when it is combined with Piretanide.Experimental
NeomycinThe serum concentration of Neomycin can be increased when it is combined with Piretanide.Approved, Vet Approved
NeosaxitoxinPiretanide may decrease the neuromuscular blocking activities of Neosaxitoxin.Investigational
NepafenacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Nepafenac.Approved, Investigational
NetilmicinThe serum concentration of Netilmicin can be increased when it is combined with Piretanide.Approved, Investigational
NicomorphineThe risk or severity of adverse effects can be increased when Nicomorphine is combined with Piretanide.Experimental
NicotineThe risk or severity of adverse effects can be increased when Piretanide is combined with Nicotine.Approved
NifenazoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Nitroaspirin.Investigational
NorepinephrineNorepinephrine may increase the hypokalemic activities of Piretanide.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Piretanide.Approved, Illicit
OleandrinThe risk or severity of adverse effects can be increased when Piretanide is combined with Oleandrin.Experimental, Investigational
Oleoyl-estroneOleoyl-estrone may increase the hypokalemic activities of Piretanide.Investigational
OlodaterolOlodaterol may increase the hypokalemic activities of Piretanide.Approved
OlopatadineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Olsalazine.Approved
OmapatrilatPiretanide may increase the hypotensive activities of Omapatrilat.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Piretanide.Approved, Illicit
OrciprenalineOrciprenaline may increase the hypokalemic activities of Piretanide.Approved
OrgoteinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Orgotein.Vet Approved
OuabainThe risk or severity of adverse effects can be increased when Piretanide is combined with Ouabain.Approved
OxaprozinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Oxaprozin.Approved
OxycodoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenbutazoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
PalmidrolThe therapeutic efficacy of Piretanide can be decreased when used in combination with Palmidrol.Experimental, Nutraceutical
PancuroniumPiretanide may decrease the neuromuscular blocking activities of Pancuronium.Approved
ParamethasoneParamethasone may increase the hypokalemic activities of Piretanide.Approved
ParecoxibThe therapeutic efficacy of Piretanide can be decreased when used in combination with Parecoxib.Approved
ParomomycinThe serum concentration of Paromomycin can be increased when it is combined with Piretanide.Approved, Investigational
ParthenolideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Parthenolide.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Piretanide.Approved, Vet Approved
PerindoprilPiretanide may increase the hypotensive activities of Perindopril.Approved
PeruvosideThe risk or severity of adverse effects can be increased when Piretanide is combined with Peruvoside.Experimental
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Piretanide.Approved
PF-00610355PF-00610355 may increase the hypokalemic activities of Piretanide.Investigational
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Piretanide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Piretanide.Experimental
Phenyl aminosalicylateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Phenyl aminosalicylate.Approved
PhenylbutazoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PhenylpropanolaminePhenylpropanolamine may increase the hypokalemic activities of Piretanide.Approved, Vet Approved, Withdrawn
PhenytoinPhenytoin may decrease the diuretic activities of Piretanide.Approved, Vet Approved
PimecrolimusThe therapeutic efficacy of Piretanide can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PipecuroniumPiretanide may decrease the neuromuscular blocking activities of Pipecuronium.Approved
PirbuterolPirbuterol may increase the hypokalemic activities of Piretanide.Approved
PirfenidoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Piretanide.Approved, Investigational
PiroxicamThe therapeutic efficacy of Piretanide can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Pirprofen.Experimental
PlazomicinThe serum concentration of Plazomicin can be increased when it is combined with Piretanide.Approved, Investigational
PranoprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasteronePrasterone may increase the hypokalemic activities of Piretanide.Approved, Investigational, Nutraceutical
Prasterone sulfatePrasterone sulfate may increase the hypokalemic activities of Piretanide.Investigational
PrednicarbatePrednicarbate may increase the hypokalemic activities of Piretanide.Approved, Investigational
PrednisoloneThe risk or severity of hypokalemia can be increased when Prednisolone is combined with Piretanide.Approved, Vet Approved
PrednisonePrednisone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
PregnenolonePregnenolone may increase the hypokalemic activities of Piretanide.Approved, Experimental, Investigational
ProbenecidThe risk or severity of adverse effects can be increased when Probenecid is combined with Piretanide.Approved, Investigational
ProcaterolProcaterol may increase the hypokalemic activities of Piretanide.Approved, Investigational
ProglumetacinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Piretanide can be decreased when used in combination with Propacetamol.Approved, Investigational
PropyphenazoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Proquazone.Experimental
ProscillaridinThe risk or severity of adverse effects can be increased when Piretanide is combined with Proscillaridin.Experimental
ProtokylolProtokylol may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
PTC299The therapeutic efficacy of Piretanide can be decreased when used in combination with PTC299.Investigational
PuromycinThe serum concentration of Puromycin can be increased when it is combined with Piretanide.Experimental
PyrantelPiretanide may decrease the neuromuscular blocking activities of Pyrantel.Approved, Vet Approved
QuinaprilPiretanide may increase the hypotensive activities of Quinapril.Approved, Investigational
RacepinephrineRacepinephrine may increase the hypokalemic activities of Piretanide.Approved
RamiprilPiretanide may increase the hypotensive activities of Ramipril.Approved
RapacuroniumPiretanide may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Piretanide.Approved
RescinnaminePiretanide may increase the hypotensive activities of Rescinnamine.Approved
ResveratrolThe therapeutic efficacy of Piretanide can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
RibostamycinThe serum concentration of Ribostamycin can be increased when it is combined with Piretanide.Approved, Investigational
RimexoloneRimexolone may increase the hypokalemic activities of Piretanide.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Piretanide is combined with Risperidone.Approved, Investigational
RitodrineRitodrine may increase the hypokalemic activities of Piretanide.Approved, Investigational
RocuroniumPiretanide may decrease the neuromuscular blocking activities of Rocuronium.Approved
RofecoxibThe therapeutic efficacy of Piretanide can be decreased when used in combination with Rofecoxib.Approved, Investigational, Withdrawn
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be increased when used in combination with Piretanide.Approved, Investigational
SalbutamolThe risk or severity of hyperkalemia can be increased when Salbutamol is combined with Piretanide.Approved, Vet Approved
SalicylamideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Salicylic acid.Approved, Investigational, Vet Approved
SalmeterolThe risk or severity of hyperkalemia can be increased when Salmeterol is combined with Piretanide.Approved
SalsalateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Salsalate.Approved
SaxagliptinThe therapeutic efficacy of Saxagliptin can be increased when used in combination with Piretanide.Approved
SemapimodThe therapeutic efficacy of Piretanide can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Piretanide can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Piretanide can be decreased when used in combination with Serrapeptase.Investigational
SisomicinThe serum concentration of Sisomicin can be increased when it is combined with Piretanide.Investigational
SitagliptinThe therapeutic efficacy of Sitagliptin can be increased when used in combination with Piretanide.Approved, Investigational
Sodium phosphate, monobasicPiretanide may increase the nephrotoxic activities of Sodium phosphate, monobasic.Approved
SpiraprilPiretanide may increase the hypotensive activities of Spirapril.Approved
SRT501The therapeutic efficacy of Piretanide can be decreased when used in combination with SRT501.Investigational
StreptomycinThe serum concentration of Streptomycin can be increased when it is combined with Piretanide.Approved, Vet Approved
SuccinylcholinePiretanide may decrease the neuromuscular blocking activities of Succinylcholine.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Piretanide can be decreased when used in combination with Sulindac.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Piretanide is combined with Sulpiride.Approved, Investigational
SuprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Piretanide can be decreased when used in combination with Suxibuzone.Experimental
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Piretanide.Approved
TarenflurbilThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tarenflurbil.Investigational
TemocaprilPiretanide may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenidapThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tepoxalin.Vet Approved
TerbutalineTerbutaline may increase the hypokalemic activities of Piretanide.Approved
TeriflunomideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Teriflunomide.Approved
Tiaprofenic acidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tiaprofenic acid.Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Piretanide.Experimental
TinoridineThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tinoridine.Investigational
TixocortolTixocortol may increase the hypokalemic activities of Piretanide.Approved, Withdrawn
TobramycinThe serum concentration of Tobramycin can be increased when it is combined with Piretanide.Approved, Investigational
Tolfenamic AcidThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tolfenamic Acid.Approved, Investigational
TolmetinThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tolmetin.Approved
TopiramateThe risk or severity of hypokalemia can be increased when Piretanide is combined with Topiramate.Approved
TramadolThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tramadol.Approved, Investigational
TrandolaprilPiretanide may increase the hypotensive activities of Trandolapril.Approved
TriamcinoloneTriamcinolone may increase the hypokalemic activities of Piretanide.Approved, Vet Approved
TribenosideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Tribenoside.Experimental
TriptolideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Triptolide.Investigational
Trolamine salicylateThe therapeutic efficacy of Piretanide can be decreased when used in combination with Trolamine salicylate.Approved
TubocurarinePiretanide may decrease the neuromuscular blocking activities of Tubocurarine.Approved
UlobetasolUlobetasol may increase the hypokalemic activities of Piretanide.Approved
ValdecoxibThe therapeutic efficacy of Piretanide can be decreased when used in combination with Valdecoxib.Approved, Investigational, Withdrawn
VecuroniumPiretanide may decrease the neuromuscular blocking activities of Vecuronium.Approved
VilanterolVilanterol may increase the hypokalemic activities of Piretanide.Approved
ZaltoprofenThe therapeutic efficacy of Piretanide can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Piretanide can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZofenoprilPiretanide may increase the hypotensive activities of Zofenopril.Experimental
Zoledronic acidThe risk or severity of hypocalcemia can be increased when Piretanide is combined with Zoledronic acid.Approved
ZomepiracThe therapeutic efficacy of Piretanide can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Yuji Chikaraishi, Yoshihisa Matsuda, Makoto Otsuka, "Amorphous piretanide, piretanide polymorphs, process for their preparation and their use." U.S. Patent US6096779, issued September, 1993.

US6096779
General References
Not Available
External Links
KEGG Drug
D01634
PubChem Compound
4849
PubChem Substance
46507197
ChemSpider
4683
ChEBI
32015
ChEMBL
CHEMBL349803
Therapeutic Targets Database
DNC001127
Wikipedia
Piretanide
ATC Codes
C03CA03 — PiretanideG01AE10 — Combinations of sulfonamides

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP3.92BIOBYTE (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0914 mg/mLALOGPS
logP2.2ALOGPS
logP2.25ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)4.68ChemAxon
pKa (Strongest Basic)-0.62ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area109.93 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.68 m3·mol-1ChemAxon
Polarizability35.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9907
Blood Brain Barrier+0.6318
Caco-2 permeable-0.6466
P-glycoprotein substrateNon-substrate0.5237
P-glycoprotein inhibitor INon-inhibitor0.8026
P-glycoprotein inhibitor IINon-inhibitor0.6635
Renal organic cation transporterNon-inhibitor0.7657
CYP450 2C9 substrateNon-substrate0.7067
CYP450 2D6 substrateNon-substrate0.8032
CYP450 3A4 substrateNon-substrate0.5997
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6747
Ames testNon AMES toxic0.6433
CarcinogenicityNon-carcinogens0.6985
BiodegradationNot ready biodegradable0.9786
Rat acute toxicity1.8427 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.848
hERG inhibition (predictor II)Inhibitor0.5391
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-3980000000-dc67e28bf67c9f799108

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylethers. These are aromatic compounds containing two benzene rings linked to each other through an ether group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylethers
Direct Parent
Diphenylethers
Alternative Parents
Phenylpyrrolidines / Aminobenzenesulfonamides / Diarylethers / Aminobenzoic acids / Benzoic acids / Benzenesulfonyl compounds / Phenoxy compounds / Phenol ethers / Dialkylarylamines / Aniline and substituted anilines
show 11 more
Substituents
Diphenylether / Aminobenzenesulfonamide / 1-phenylpyrrolidine / Diaryl ether / Aminobenzoic acid / Aminobenzoic acid or derivatives / Benzenesulfonamide / Benzoic acid / Benzoic acid or derivatives / Benzenesulfonyl group
show 32 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium:potassium:chloride symporter activity
Specific Function
Electrically silent transporter system. Mediates sodium and chloride reabsorption. Plays a vital role in the regulation of ionic balance and cell volume.
Gene Name
SLC12A1
Uniprot ID
Q13621
Uniprot Name
Solute carrier family 12 member 1
Molecular Weight
121449.13 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Drug created on June 13, 2005 07:24 / Updated on August 02, 2018 04:58